ZLAB Stock Price, Chart, Stats & News
Zai Lab Limited (ZLAB) does not currently pay a dividend.
ZLAB chart
Fundamentals
Gross margin | 58.47% |
Operating margin | -49.86% |
Pretax margin | -38.78% |
Net margin | -38.15% |
Effective tax rate | 1.64% |
ROA | -14.97% |
ROE | -22.81% |
D/E | 0.31x |
Interest coverage ratio | -44.04x |
ZLAB valuation
P/E | – |
P/S | 4.33x |
P/B | 2.78x |
P/CF | -13.20x |
P/FCF | -12.54x |
P/OCF | -13.20x |
PEG | -0.57x |
EV multiple | -15.47x |
About
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders. Currently available products in their portfolio include Zejula, a once-daily small-molecule PARP 1/2 inhibitor; Optune, a medical device leveraging tumor treating fields; NUZYRA, an antimicrobial agent for specific acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors.
Similar securities
Based on sector and market capitalization
